NO996433L - Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav - Google Patents

Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav

Info

Publication number
NO996433L
NO996433L NO996433A NO996433A NO996433L NO 996433 L NO996433 L NO 996433L NO 996433 A NO996433 A NO 996433A NO 996433 A NO996433 A NO 996433A NO 996433 L NO996433 L NO 996433L
Authority
NO
Norway
Prior art keywords
methods
drugs
preparation
new formulations
formulations
Prior art date
Application number
NO996433A
Other languages
English (en)
Other versions
NO332166B1 (no
NO996433D0 (no
Inventor
Neil P Desai
Patrick Soon-Shiong
Shlomo Magdassi
David C Sahadevan
Original Assignee
Vivorx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/926,155 external-priority patent/US6096331A/en
Application filed by Vivorx Pharmaceuticals Inc filed Critical Vivorx Pharmaceuticals Inc
Publication of NO996433D0 publication Critical patent/NO996433D0/no
Publication of NO996433L publication Critical patent/NO996433L/no
Publication of NO332166B1 publication Critical patent/NO332166B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO19996433A 1997-06-27 1999-12-23 Formuleringer av paklitaksel NO332166B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5102197P 1997-06-27 1997-06-27
US08/926,155 US6096331A (en) 1993-02-22 1997-09-09 Methods and compositions useful for administration of chemotherapeutic agents
PCT/US1998/013272 WO1999000113A1 (en) 1997-06-27 1998-06-26 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof

Publications (3)

Publication Number Publication Date
NO996433D0 NO996433D0 (no) 1999-12-23
NO996433L true NO996433L (no) 2000-02-14
NO332166B1 NO332166B1 (no) 2012-07-09

Family

ID=26728969

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19996433A NO332166B1 (no) 1997-06-27 1999-12-23 Formuleringer av paklitaksel
NO20120338A NO340319B1 (no) 1997-06-27 2012-03-22 Sammensetning som omfatter nanopartikler som omfatter taxan for cancerbehandling.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20120338A NO340319B1 (no) 1997-06-27 2012-03-22 Sammensetning som omfatter nanopartikler som omfatter taxan for cancerbehandling.

Country Status (18)

Country Link
US (2) US20080161382A1 (no)
EP (1) EP1023050B1 (no)
JP (2) JP4865937B2 (no)
KR (3) KR100789008B1 (no)
CN (2) CN100525748C (no)
AU (1) AU8266298A (no)
BR (1) BRPI9810945B8 (no)
CA (1) CA2294981C (no)
DK (1) DK1023050T3 (no)
ES (1) ES2435944T3 (no)
HU (1) HU230338B1 (no)
IL (2) IL133672A0 (no)
MX (1) MX337149B (no)
NO (2) NO332166B1 (no)
NZ (2) NZ502500A (no)
PT (1) PT1023050E (no)
SG (1) SG113402A1 (no)
WO (1) WO1999000113A1 (no)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US20070116761A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8137684B2 (en) * 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ES2435944T3 (es) * 1997-06-27 2013-12-26 Abraxis Bioscience, Llc Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
CA2371912C (en) * 1999-05-21 2010-02-16 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
EP1267946A4 (en) 2000-02-28 2008-07-02 Genesegues Inc SYSTEM AND METHOD FOR ENCAPSULATING NANOCAPSULES
US7473433B2 (en) 2000-12-21 2009-01-06 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
KR100426636B1 (ko) * 2001-05-18 2004-04-08 한국과학기술연구원 주사 가능한 젤 상의 조성물 및 그의 제조방법
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
EP1478343B1 (en) 2001-10-15 2017-03-22 Crititech, Inc. Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
US20030207907A1 (en) 2002-05-03 2003-11-06 Iversen Patrick L. Delivery of microparticle-conjugated drugs for inhibition of stenosis
ITMI20021392A1 (it) * 2002-06-25 2003-12-29 Nicox Sa Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
JP4454019B2 (ja) 2002-07-15 2010-04-21 アルコン，インコーポレイテッド 眼薬送達のための生体侵食性フィルム
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
IL150906A0 (en) * 2002-07-25 2003-02-12 Yissum Res Dev Co Diagnostic microspheres
DE10234784A1 (de) * 2002-07-30 2004-02-19 Günenthal GmbH Intravenös applizierbare, pharmazeutische Darreichungsform
US7838034B2 (en) 2002-07-30 2010-11-23 Grunenthal Gmbh Intravenous pharmaceutical form of administration
KR100871529B1 (ko) * 2002-12-09 2008-12-05 치아-시앙 수 정맥내 주사용으로 적합한 피브리노겐 입자의 제조방법
EP1585548B1 (en) * 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
CN1700906A (zh) 2003-02-03 2005-11-23 新药物公司 稳定的无菌过滤性脂质体包封的紫杉烷和其他抗肿瘤药物
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
CN1303994C (zh) * 2003-03-03 2007-03-14 浙江海正药业股份有限公司 紫杉醇囊泡注射剂及其制备方法
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
JP4961213B2 (ja) * 2004-01-21 2012-06-27 ザ・スクール・オブ・ファーマシー マイクロ粒子の製造方法
KR100578382B1 (ko) 2004-07-16 2006-05-11 나재운 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
EP1908511A1 (en) * 2005-06-29 2008-04-09 Mitsubishi Chemical Corporation Granule dispersion composition, process for producing the same, and granular material and medicine
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
US8034765B2 (en) * 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
EP1931417A2 (en) * 2005-09-30 2008-06-18 Transcutaneous Technologies Inc. Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles
CA2626016A1 (en) * 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
JP5368300B2 (ja) * 2006-06-08 2013-12-18 スリーエム イノベイティブ プロパティズ カンパニー ポリマービーズおよびポリマービーズの製造方法
JPWO2008041553A1 (ja) 2006-09-26 2010-02-04 アステラス製薬株式会社 タクロリムス徐放性製剤
PT2117520T (pt) 2006-12-14 2018-12-04 Abraxis Bioscience Llc Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
LT2481402T (lt) 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
JP5302340B2 (ja) 2008-01-30 2013-10-02 カンザス大学 リンパ管内化学療法薬物担体
CN101965195A (zh) 2008-03-05 2011-02-02 巴克斯特国际公司 用于药物投送的组合物和方法
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR20150136137A (ko) * 2008-04-10 2015-12-04 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 및 그의 용도
WO2010003057A2 (en) 2008-07-03 2010-01-07 Mayo Foundation For Medical Education And Research Treating cancer
KR101043407B1 (ko) * 2009-02-19 2011-06-22 한국과학기술연구원 암 표적성이 우수한 단백질 복합체 및 이의 제조방법
KR101066197B1 (ko) 2009-04-06 2011-09-20 한국생명공학연구원 코엔자임 ｑ10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물
EP2416650B1 (en) * 2009-04-10 2020-02-26 Abraxis BioScience, LLC Nanoparticle formulations and uses therof
CN102460167B (zh) 2009-04-15 2015-07-22 阿布拉科斯生物科学有限公司 不含朊病毒的纳米颗粒组合物和方法
JP2013503174A (ja) * 2009-08-25 2013-01-31 アブラクシス バイオサイエンス， エルエルシー タキサンおよびヘッジホッグ阻害剤のナノ粒子組成物を使用する併用療法
JP4856752B2 (ja) * 2009-11-30 2012-01-18 ホソカワミクロン株式会社 薬物含有ナノ粒子の製造方法
CA2784826A1 (en) * 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for stable liquid drug formulations
EP2531173B1 (en) * 2010-02-03 2018-09-26 Oncbiomune, L.L.C. Taxane- and taxoid-protein compositions
CN104784121A (zh) 2010-03-26 2015-07-22 阿布拉科斯生物科学有限公司 治疗肝细胞癌的方法
WO2011123393A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
NZ602385A (en) 2010-03-29 2014-08-29 Abraxis Bioscience Llc Methods of treating cancer
JP5824511B2 (ja) 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
MY166014A (en) * 2010-06-07 2018-05-21 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
KR101007948B1 (ko) 2010-08-13 2011-01-14 김지훈 스팀을 이용한 고무 블록의 성형 방법
US9782342B2 (en) 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
CN102670518B (zh) * 2011-03-14 2014-08-20 齐鲁制药有限公司 一种难溶性药物球形颗粒的制备方法
WO2012131399A1 (en) 2011-04-01 2012-10-04 Astrazeneca Ab Therapeutic treatment
HRP20200793T1 (hr) 2011-05-09 2020-10-16 Mayo Foundation For Medical Education And Research Liječenje raka
PT2785349T (pt) 2011-11-30 2019-12-11 Astrazeneca Ab Tratamento combinado de cancro
PT2790675T (pt) 2011-12-14 2019-09-23 Abraxis Bioscience Llc Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas
KR101455921B1 (ko) * 2012-01-30 2014-11-12 성균관대학교산학협력단 수난용성 약물을 내부에 포함하는 알부민 나노입자 제조방법
NZ700073A (en) 2012-04-04 2016-08-26 Halozyme Inc Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
CA2917407C (en) 2012-10-01 2023-03-14 Mayo Foundation For Medical Education And Research Complexes containing albumin-containing nanoparticles and antibodies to treat cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20150352050A1 (en) * 2012-11-15 2015-12-10 Utah-Inha Dds & Advanced Therapeutics Research Center Biodegradable microbeads with improved anticancer drug adsorptivity, containing albumin and dextran sulfate, and preparation method therefor
WO2014084530A1 (ko) 2012-11-27 2014-06-05 재단법인 유타 인하 디디에스 및 신의료기술개발공동연구소 음이온성 고분자를 포함하는 항암제 흡착능력이 향상된 생분해성 마이크로 비드 및 이의 제조방법
CN103908432B (zh) * 2013-01-02 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种伊沙匹隆白蛋白的冻干组合物及其制备方法
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CA2900136C (en) 2013-03-04 2021-05-04 Astrazeneca Ab Combination treatment
ES2804323T3 (es) * 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
KR101329646B1 (ko) 2013-05-02 2013-11-14 주식회사 지니스 표적지향증폭형 항암나노입자 및 이의 제조방법
IL228528A (en) 2013-09-17 2015-01-29 Technion Res & Dev Foundation Potato-based nanoparticles
WO2015051349A1 (en) * 2013-10-04 2015-04-09 Sorrento Therapeutics, Inc. Treating metastatic cancer with micellular paclitaxel
CN104758942A (zh) * 2014-01-02 2015-07-08 国家纳米科学中心 基于蛋白质的药理活性物质组合物及其制备方法和应用
WO2015152433A1 (en) 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
WO2015187194A1 (en) * 2014-06-01 2015-12-10 Crititech, Inc. Use of paclitaxel particles
US20150352176A1 (en) * 2014-06-06 2015-12-10 Newport Research, Inc. Oil-free and fat-free aqueous suspensions of cyclosporin
CA2950926A1 (en) 2014-06-13 2015-12-17 Mayo Foundation For Medical Education And Research Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas
JP6600651B2 (ja) 2014-06-16 2019-10-30 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 骨髄腫の治療
EP3188716B1 (en) 2014-09-03 2022-10-26 GeneSegues, Inc. Therapeutic nanoparticles and related compositions, methods and systems
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
JP6921759B2 (ja) 2015-06-04 2021-08-18 クリティテック・インコーポレイテッド 捕集装置および使用法
EP3313401B1 (en) 2015-06-29 2021-10-06 Abraxis BioScience, LLC Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
AU2016323770A1 (en) 2015-09-16 2018-03-29 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
CN105412024B (zh) * 2015-12-14 2018-03-30 广州帝奇医药技术有限公司 靶向疏水性抗肿瘤药物纳米制剂及其制备方法
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
US10328216B2 (en) * 2016-01-20 2019-06-25 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispensible spray dried powders suitable for inhalation
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432926A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS
CA3018340A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
SG10201913409VA (en) 2016-04-04 2020-03-30 Crititech Inc Methods for solid tumor treatment
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN105944109B (zh) * 2016-05-03 2019-06-11 四川大学 一种肾小球靶向的蛋白纳米颗粒药物组合物及其用途
WO2018038253A1 (ja) * 2016-08-26 2018-03-01 哲治 奥野 微小ナノ化薬剤およびその利用
EP3506950A1 (en) 2016-09-01 2019-07-10 Mayo Foundation for Medical Education and Research Methods and compositions for targeting t-cell cancers
JP7525999B2 (ja) 2016-09-01 2024-07-31 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
RU2756892C2 (ru) 2016-09-06 2021-10-06 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
MX2019003988A (es) * 2016-10-10 2019-08-14 Abraxis Bioscience Llc Formulaciones de nanoparticulas y sus metodos de fabricacion y uso.
JP2020514359A (ja) 2017-03-15 2020-05-21 ディーエフビー ソリア リミテッド ライアビリティ カンパニー タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
CN115919815A (zh) 2017-06-14 2023-04-07 克里蒂泰克公司 治疗肺部疾病的方法
EP3648741A4 (en) * 2017-07-07 2021-05-05 DFB Pharmaceuticals, LLC TREATMENT OF HYPERPLASTIC TISSUE GROWTH INCLUDING BENEFIT PROSTATE HYPERPLASIA (BPH) BY DIRECT INJECTION OF ANTINEOPLASTIC AGENT
CN107510600A (zh) * 2017-08-07 2017-12-26 苏州大学 一种制备药用固体微粒的设备及方法
KR20200064112A (ko) 2017-10-03 2020-06-05 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
US11819488B2 (en) 2018-02-23 2023-11-21 Rhnanopharma Nanosuspensions of salsalate and methods of using the same
KR20200132963A (ko) 2018-03-16 2020-11-25 디에프비 소리아, 엘엘씨 탁산의 나노입자를 사용하는 자궁경부 상피내 신생물 (cin) 및 자궁경부 암의 치료를 위한 국소적 요법
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
BR112020021054A2 (pt) 2018-04-25 2021-02-17 Ethris Gmbh composição, processo para a preparação de uma composição, e, composições sólida e para uso
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020249825A1 (en) * 2019-06-14 2020-12-17 Folium Biosciences Europe B.V. Method for micro-encapsulation of natural ingredients by means of contacting with supercritical gas
KR20220106758A (ko) 2019-10-28 2022-07-29 아브락시스 바이오사이언스, 엘엘씨 알부민 및 라파마이신의 제약 조성물
JP2024534175A (ja) * 2021-10-14 2024-09-18 スカイ・セラピューティクス・カンパニー・リミテッド 有機物、無機物またはこれらの塩からなるナノ分子会合体及びその製造方法
KR102526793B1 (ko) * 2021-11-03 2023-04-28 주식회사 에스엔바이오사이언스 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법
CN116672300A (zh) * 2022-02-23 2023-09-01 苏州博创同康医药科技有限公司 一种载药纤维材料及其制备方法和用途
EP4504165A1 (en) 2022-04-05 2025-02-12 Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
EP4501320A1 (en) * 2023-08-02 2025-02-05 IQ medical GmbH A method of preparing an aqueous dispersion of nanoparticles
KR102683810B1 (ko) * 2024-03-26 2024-07-11 큐어라벨 주식회사 글루타치온, 아스코빅애씨드 및 항산화 활성을 가지는 유용성 생리활성물질을 포함하는 나노 입자의 제조방법 및 이를 함유하는 화장료 조성물

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2660556A (en) * 1952-09-08 1953-11-24 Donald G Butler Electric arc production of combustible gases
US3536074A (en) * 1968-03-29 1970-10-27 Alfred Aufhauser Oral administration of a pill,tablet or capsule
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4357259A (en) * 1977-08-01 1982-11-02 Northwestern University Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres
US4329332A (en) * 1978-07-19 1982-05-11 Patrick Couvreur Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
DE3119383A1 (de) * 1981-05-15 1982-12-02 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinodpraeparaten
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4914084A (en) * 1984-05-09 1990-04-03 Synthetic Blood Corporation Composition and method for introducing heme, hemoproteins, and/or heme-hemoprotein complexes into the body
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4752567A (en) * 1984-06-21 1988-06-21 Janssen Pharmaceutica N.V. Method of visualizing individual submicroscopic metal particles
JPH07106977B2 (ja) * 1984-12-14 1995-11-15 ゲルゲリイ、ゲルハルト 疎水性又は難溶性物質の粒子の親水化の方法
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
EP0256119A4 (en) * 1986-02-10 1988-08-23 Liposome Technology Inc MAINTAINED LIPOSOME DELIVERY SYSTEM.
US4966773A (en) * 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US4929446A (en) * 1988-04-19 1990-05-29 American Cyanamid Company Unit dosage form
US5041292A (en) * 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US4957656A (en) * 1988-09-14 1990-09-18 Molecular Biosystems, Inc. Continuous sonication method for preparing protein encapsulated microbubbles
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
CA2013485C (en) * 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5441739A (en) * 1990-06-22 1995-08-15 The Regents Of The University Of California Reduced and controlled surface binding of biologically active molecules
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
EP0504340B1 (en) * 1990-10-05 1995-06-21 BRACCO International B.V. Method for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography
US20030087985A1 (en) * 1990-10-15 2003-05-08 Hubbell Jeffrey A. Gels for encapsulation of biological materials
DE69124357T2 (de) * 1991-01-15 1997-07-10 Hemosphere Inc Protein Nanomatrizen und Verfahren zur Herstellung
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5143716A (en) * 1991-02-01 1992-09-01 Unger Evan C Phosphorylated sugar alcohols, Mono- and Di-Saccharides as contrast agents for use in magnetic resonance imaging of the gastrointestinal region
JPH06511481A (ja) * 1991-07-05 1994-12-22 ユニバーシティ オブ ロチェスター 気泡を取り込む超微小非凝集多孔質粒子
US5250236A (en) * 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
US5233995A (en) * 1991-11-21 1993-08-10 Sterling Winthrop Inc. Encapsulated particles useful as contrast agents in ultrasound and x-ray imaging compositions and methods
DE69329073T2 (de) * 1992-03-23 2001-01-18 Georgetown University, Washington In liposomen verkapseltes taxol und verwendungsverfahren
US5334640A (en) * 1992-04-08 1994-08-02 Clover Consolidated, Ltd. Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
AU4406793A (en) * 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
DE4220624A1 (de) * 1992-06-24 1994-01-05 Zahnradfabrik Friedrichshafen Drehschieberventil, insbesondere für Hilfskraftlenkungen
ZA935111B (en) * 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US20070116761A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
JP3746293B2 (ja) * 1993-02-22 2006-02-15 アメリカン バイオサイエンス、インコーポレイテッド 生物製剤のインビボ送達の方法とそのための組成物
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5554730A (en) * 1993-03-09 1996-09-10 Middlesex Sciences, Inc. Method and kit for making a polysaccharide-protein conjugate
DE69435120D1 (de) * 1993-05-13 2008-09-04 Poniard Pharmaceuticals Inc Ein Inhibitor für glatte Gefässmuskelzellen für therapeutische Nutzung
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
ES2255477T5 (es) * 1993-07-29 2010-04-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Uso de paclitaxel y sus derivados en la fabricacion de un medicamento para el tratamiento de reestenosis.
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
ATE277640T1 (de) * 1994-03-07 2004-10-15 Dow Chemical Co Bioaktive und/oder gezielte dendrimere-konjugate enthaltend genetisches material
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
ES2078190B1 (es) * 1994-05-20 1996-08-01 Cusi Lab Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico.
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
WO1996041236A1 (en) * 1995-06-07 1996-12-19 The Regents Of The University Of California Therapeutic microdevices and methods of making and using same
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
CN1148957A (zh) * 1996-09-02 1997-05-07 张海茹 紫杉醇水溶性粉针剂及其制备方法
US8137684B2 (en) * 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ES2435944T3 (es) * 1997-06-27 2013-12-26 Abraxis Bioscience, Llc Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
CA2369740A1 (en) * 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
EP1585548B1 (en) * 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
WO2006089290A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
US8034765B2 (en) * 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability

Also Published As

Publication number Publication date
IL133672A0 (en) 2001-04-30
WO1999000113A9 (en) 1999-04-08
EP1023050B1 (en) 2013-09-25
KR100789008B1 (ko) 2007-12-26
WO1999000113A1 (en) 1999-01-07
SG113402A1 (en) 2005-08-29
CA2294981A1 (en) 1999-01-07
KR20050042507A (ko) 2005-05-09
JP2011219482A (ja) 2011-11-04
CN100525748C (zh) 2009-08-12
AU8266298A (en) 1999-01-19
BRPI9810945B1 (pt) 2016-12-27
HUP0003972A2 (hu) 2001-08-28
CN1267214A (zh) 2000-09-20
DK1023050T3 (da) 2013-10-14
KR100904931B1 (ko) 2009-06-29
BRPI9810945B8 (pt) 2021-05-25
US20080160095A1 (en) 2008-07-03
KR20010014254A (ko) 2001-02-26
NO20120338A1 (no) 2000-02-14
JP2002507976A (ja) 2002-03-12
CA2294981C (en) 2012-04-03
EP1023050A4 (en) 2006-08-30
NZ502500A (en) 2002-03-28
HK1030543A1 (en) 2001-05-11
HU230338B1 (hu) 2016-02-29
NZ525580A (en) 2004-08-27
CN1515246A (zh) 2004-07-28
ES2435944T3 (es) 2013-12-26
JP5405527B2 (ja) 2014-02-05
KR100923172B1 (ko) 2009-10-22
IL222002B (en) 2018-02-28
MX337149B (es) 2016-02-15
NO340319B1 (no) 2017-03-27
NO332166B1 (no) 2012-07-09
KR20070091051A (ko) 2007-09-06
HUP0003972A3 (en) 2002-10-28
PT1023050E (pt) 2013-12-04
US20080161382A1 (en) 2008-07-03
JP4865937B2 (ja) 2012-02-01
CN100462066C (zh) 2009-02-18
NO996433D0 (no) 1999-12-23
EP1023050A1 (en) 2000-08-02
BR9810945A (pt) 2002-02-05

Similar Documents

Publication Publication Date Title
NO996433D0 (no) Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav
NO306253B1 (no) Arylsulfonyl-hydroksamsyre-derivater, anvendelse derav og farmasöytisk preparat
IS5409A (is) Útskipt karboxamídóþíasól, framleiðsla þeirra og lyfjablöndur sem innihalda þau
IS1846B (is) Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur
NO308298B1 (no) Substituerte kinazolinderivater, anvendelse derav og farmasøytiske preparater inneholdende dem
NO20024176L (no) Farmasöytiske preparater inneholder derivater av 3-amino- azetidin, de nye derivater og deres fremstilling
NO2009028I1 (no) Kinazolin-derivater, anvendelse og fremstilling derav, samt farmasøytisk preparat
NO20016277D0 (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske formuleringer
DK0876362T3 (da) Nye taxoider, deres fremstilling og farmaceutiske præparater deraf
NO307925B1 (no) Bicykliske aromatiske forbindelser, anvendelse derav, og farmasøytiske og kosmetiske preparater
DK0826673T3 (da) Acetamidderivater, fremgangsmåde til fremstilling deraf og medicinske præparater
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
NO20000932L (no) Farmasøytisk preparat for kombinasjon av piperidinoalkanol og dekongestant
NO985368D0 (no) Substituerte imidazolidinderivater, deres fremstilling, deres anvendelse og farmas°ytiske preparater inneholdende forbindelsene
NO952677D0 (no) Nye dihydropyrrolopyridinon- og oksazolopyridinonforbindelser, deres fremstilling og farmasöytiske preparater
DK0991654T3 (da) Hidtil ukendte derivater af 2-(iminomethyl)aminophenyl, deres fremstilling, deres anvendelse til medikamenter og farmaceutiske præparater indeholdende samme
NO984878D0 (no) Fremstilling og anvendelse som medikamenter av 3-alkoksypyridin-2-karboksylsyreamidestere
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
NO307510B1 (no) Bicykliske aromatiske forbindelser, deres anvendelse og farmasøytiske og kosmetiske preparater derav
NO984309D0 (no) Nye imidazolidinderivater, deres fremstilling, deres anvendelse og farmas°ytiske preparater inneholdende disse
DK0994706T3 (da) Præparater til oral indgivelse af taxaner og anvendelse deraf
NO994659D0 (no) Nye pyridinderivater og farmasöytiske preparater inneholdende slike
NO983472D0 (no) Taxoider, deres fremstilling og farmas°ytiske preparater inneholdende taxoidene
NO20021949L (no) Nye hormonpreparater og anvendelse av dem
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme

Legal Events

Date Code Title Description
MK1K Patent expired